Abstract. Sorafenib is an oral multikinase inhibitor that acts by inhibiting tumor growth and disrupting tumor microvasculature through antiproliferative, anti-angiogenic and proapoptotic effects. It exerts these effects via inhibition of multiple targets including Raf serine/threonine kinases, vascular endothelial growth factor receptor tyrosine kinases; VEGFR-1, VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor β (PDGFR-β). Current literature shows that the deregulated signaling through these receptors is commonly seen in human tumors. In addition, sorafenib is also shown to induce apoptosis through downregulation of Mcl-1 in many cancer types. Hence, sorafenib as a single agent has shown promising activity in some cancers such as renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and thyroid cancers. Currently, the drug holds FDA approval for the treatment of advanced RCC and unresectable HCC. However, many clinical studies have indicated several limitations to the application of sorafenib as a single agent in various other cancers. Owing to these reasons and the potential of sorafenib to synergize with other anticancer therapies, its combination with other targeted agents and chemotherapy has been widely explored with promising results. In addition, it has also shown synergistic results when combined with radiation. This review summarizes the current basic and clinical studies on the effects and mechanisms of sorafenib either administered alone or in combination with other anticancer treatments.

Contents

1. Introduction
2. Sorafenib targets
3. Expression of sorafenib targets and mechanisms of action in cancers
4. Sorafenib monotherapy
5. Sorafenib combination therapy
6. Conclusions

1. Introduction

Since the 1980s, the field of cancer treatment has experienced a major paradigm shift from broad-spectrum cytotoxic chemotherapeutics to the development of targeted therapies tailored to inhibit cancer-specific pathways (1). This change was prompted by the limitations of the treatment mainstays in those days, which were surgery, chemotherapy and radiotherapy. Surgery was limited to early non-metastatic diseases, however, research demonstrates that solid tumors are frequently metastatic at presentation (2). Radiation and chemotherapy has limited capacity to discriminate between cancerous and normal cells and hence, results in severe side effects (3). Furthermore, solid tumors are inherently resistant to both radiation and chemotherapy. Therefore, the rationale for development of molecular targeted therapies was to overcome drug resistance, to make malignant cells more susceptible to suppression and damage whilst avoiding substantial toxicity to the rest of the body tissues and also to provide a higher therapeutic index.

The molecular targeted therapies include monoclonal antibodies, tyrosine kinase inhibitors, rapamycin pathway inhibitors, proteasome inhibitors and inhibitors of Raf kinase (4). Many of these drugs have shown therapeutic benefit in various cancers, however, several challenges are yet to be conquered by the developers. These include overcoming certain amount of acquired resistance in cancer cells, selecting suitable dosage schedules, determining the stage to start treatment and identifying relevant combination regimens. In addition, there appears to be a weakness in identifying the most important targets in cancer, as well as an inability to design drugs that would specifically confront the selected targets (4). Hence, the utility of successful targeted therapies is yet to be attained in many cancer patients.

Since the implication of deregulated Raf kinases in tumorigenesis and progression in many solid tumors, previous
studies aimed at identifying a drug that will interfere with these targets. This led to the discovery of sorafenib in the late 1990s (1). Sorafenib acts on both the tumor and its microvasculature via multiple targets (5). This explains its broad activity in many tumor types and also its clinical effect in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In spite of this, sorafenib monotherapy was shown to be less successful in certain cancers such as sarcomas and melanomas due to reasons such as patient insensitivity and drug resistance. However, the multiple targets of sorafenib make it an attractive choice for combination therapy. Therefore, the combination of sorafenib with other drugs has been extensively investigated, indicating clinical benefits in many cancer types (6).

This review aims to explore: i) sorafenib targets and mechanisms of inhibition in several cancers, ii) sorafenib monotherapy and iii) combination therapy with chemotherapy, radiotherapy and other targeted agents.

2. Sorafenib targets

Sorafenib is a dual action multikinase inhibitor that targets both tumor cells and cells of the tumor vasculature. It inhibits tumor proliferation by potently inhibiting the Raf serine/threonine kinases: Raf-1, wild-type B-Raf and oncogenic B-Raf V600E kinases in the MAPK pathway (7) (Fig. 1). These kinases are pivotal regulators of cellular proliferation and survival and in addition Raf-1 also interacts directly with anti-apoptotic and apoptotic regulatory proteins to prolong cell survival (1). Sorafenib has shown dose-dependent inhibition of tumor proliferation in various human cancer cell lines containing oncogenic K-Ras or B-Raf mutations, including breast, colon and pancreatic cancers (5).

Sorafenib also potently inhibits proangiogenic vascular endothelial growth factor receptor tyrosine kinases; VEGFR-1, VEGFR-2, VEGFR-3 and the platelet-derived growth factor receptor β (PDGFR-β) (5). These receptor tyrosine kinases (RTKs) utilize the MAPK pathway to induce proliferation and prolong the survival of vascular endothelial cells, which gives rise to new blood vessels (2). Also they promote the proliferation, survival and recruitment of pericytes, which stabilize the newly formed blood vessels.

In addition, sorafenib has been shown to induce apoptosis in several tumor cell lines (5). Although this mechanism is not fully understood, it is commonly observed that sorafenib inhibits phosphorylation of the initiation factor eIF4E resulting in loss of the anti-apoptotic protein: myeloid cell leukemia-1 (Mcl-1). The downregulation of Mcl-1 by sorafenib causes the release of cytochrome c from mitochondria into the cytoplasm. This activates caspase and induces apoptotic cell death.

3. Expression of sorafenib targets and mechanisms of action in cancers

Research has shown that in about 30% of human cancers, signaling through the Raf kinase isoforms is deregulated (1). Activating oncogenic mutations in B-Raf, such as B-Raf V600E is present in 63% of melanomas and up to 50% of papillary thyroid carcinomas. Wild-type Raf-1 is often hyper-activated in several human solid tumors due to constitutively active upstream oncogenic Ras mutants or overexpression of upstream growth factors or their RTKs. In addition, activated Ras oncogenes such as K-Ras are prevalent in human solid tumors. This includes 90% of pancreatic, 45% of colorectal, 30% HCCs, 35% non-small cell lung cancers (NSCLC), 15% of melanomas and 10% kidney tumors. Also Raf-1 hyper-activation in the absence of oncogenic mutations is commonly seen in RCC and HCC and it is associated with poor prognosis in ovarian and androgen-insensitive prostate cancer (1).

VEGF is expressed in ~30-60% of most solid tumors and in up to 100% of RCC (8). Overall different tumors have been shown to express different VEGF ligands. For instance VEGFR-1 and VEGFR-2 are upregulated in intratumoral endothelial cells, circulating endothelial cells, endothelial progenitor cells and tumor cells.

As sorafenib acts via various targets, its mechanism of action in different cancers is different depending on the expression of targets. It may be impossible to determine the role of individual targets in cancers but the preclinical data can be used to understand the contribution of various mechanisms of sorafenib in different cancers (5). These mechanisms are summarized in Table I.

4. Sorafenib monotherapy

Clinical trials investigating the effect of sorafenib as a single agent have yielded encouraging results in some human solid tumors. Currently sorafenib is approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced RCC and those with unresectable HCC (9). It is also approved by the European Medicine Agency (EMEA) for the treatment of patients with HCC and advanced RCC in whom previous interferon (IFN)-α or interleukin (IL)-2-based therapy had failed or in those considered to be unsuitable for such therapy.

Renal cell carcinoma. Two randomized controlled clinical trials established the safety and efficacy of sorafenib in...
patients with advanced RCC. The first one was a phase III randomized, double-blind, placebo-controlled TARGET trial with 903 patients who had failed previous standard therapy (10). These patients were randomly assigned to either sorafenib 400 mg twice daily orally or placebo. The primary end-point was overall survival. Crossover from placebo to sorafenib was permitted after a single planned analysis of progression-free survival (PFS), which showed statistically significant benefit over placebo. The median PFS for sorafenib group was 5.5 months while that of placebo group was 2.8 [hazard ratio (HR)=0.44, 95% confidence interval (CI), 0.35-0.55; P<0.01]. The most common adverse effects were diarrhea, rash, fatigue and hand-foot skin reactions (HFSR). Hypertension and cardiac ischemia were rare serious adverse events, more common in the sorafenib group (10). The final overall survival data showed a statistically significant benefit in the sorafenib group after the post-crossover placebo survival data was censored (17.8 vs. 14.3 months; HR=0.78; P=0.029) (9).

The other study was a phase II randomized discontinuation trial, which evaluated the effect of sorafenib on 65 patients who had stable disease after 12 weeks on sorafenib (11). The primary end-point was the percentage of patients remaining progression-free at 24 weeks after sorafenib initiation. At 24 weeks, 50% of sorafenib-treated patients were progression-free compared to 18% of placebo-treated patients (P=0.0077). Median PFS was significantly longer with sorafenib (24 weeks).

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Study</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCC</td>
<td>Effects of sorafenib on RCC (40)</td>
<td>Sorafenib showed potent tumor growth inhibition and tumor stasis which strongly correlated with decreased tumor angiogenesis due to inhibition of PDGF-mediated endothelial and pericyte survival.</td>
</tr>
<tr>
<td>HCC</td>
<td>Effects of sorafenib in HCC cell lines (3)</td>
<td>Antitumor activity was observed and was attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).</td>
</tr>
<tr>
<td>Breast, colon and NSCLC</td>
<td>In vitro effects of sorafenib on various kinase residues and breast cancer, colon cancer and NSCLC cell lines (7)</td>
<td>Breast cancer: inhibition of the MAPK pathway and inhibition of angiogenesis. In the MDA-MB-231 model, sorafenib induced tumor shrinkage, inhibited proliferation and angiogenesis. Different mechanisms in different colon cancer models. HT-29: inhibition of both MAPK and angiogenesis pathways; Colo-205: inhibition of angiogenesis only; A549 NSCLC models: inhibited Mcl-1 and induced apoptosis-independent of the MAPK pathway.</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Identified the role of V599E B-Raf in melanoma and mechanism of its tumorigenesis (42)</td>
<td>Inhibition of V599E B-Raf with sorafenib reduced activity of MAPK cascade, inhibited vascular development by decreased VEGF secretion, subsequent increased in tumor cell apoptosis.</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>A preclinical study that evaluated the activity of sorafenib on pancreatic cancer cell lines (43)</td>
<td>Exerted antiproliferative effects independent of RAF/MEK/ERK pathway. Highest levels of apoptosis seen in t3m4 cells associated with RAF/AKT/STAT3 signaling. U0126-induced MEK inhibition did not induce apoptosis in any cell line, reinforcing the hypothesis of a MEK/ERK-independent mechanism by sorafenib. Mcl-1 appears to play an important role in apoptosis.</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>A preclinical study that analyzed the cytotoxic effect of sorafenib on lymphoma cells (44)</td>
<td>Inhibition of MAPK14 and panAKT phosphorylation.</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia</td>
<td>A preclinical study that evaluated the mechanism and activity of sorafenib in chronic lymphocytic leukemia (45)</td>
<td>Sorafenib-induced cell death of CLL cells accompanied by a loss of Mcl-1.</td>
</tr>
</tbody>
</table>
than with placebo (6 weeks; P=0.087). After this sorafenib was restarted in patients who were on placebo with a median PFS of 24 weeks. Common side effects were skin rash/desquamation, HFSR and fatigue. Although patients on sorafenib experienced more side effects, the overall rate of events was low and the toxic effects were moderate and easily manageable (10,12). Bukowski et al demonstrated that sorafenib shows clinical benefit without adversely impacting overall quality-of-life (QOL) and has a positive impact on some individual symptoms and concerns (13).

**Hepatocellular carcinoma.** HCC is a highly vascularized, VEGF-driven tumor. No therapeutically beneficial drug in advanced inoperable HCC was available until 2007 (9). It came as a breakthrough discovery in the field when sorafenib improved overall survival (OS) in advanced HCC patients in a phase II randomized placebo-controlled trial (14). Subsequently two phase III randomized double-blind placebo-controlled trials were conducted.

The SHARP trial evaluated 602 patients with advanced HCC who had not received prior systemic therapy, to receive either sorafenib or placebo with the primary endpoint being OS (14). The median OS was significantly longer in the sorafenib group than in the placebo group (10.7 vs. 7.9 months; P<0.001). The time to radiologic progression was also significantly longer in the sorafenib group compared to placebo.
group (5.5 vs. 2.8 months; P<0.001) and the estimated PFS rate at 4 months was 62 and 42%, respectively. Moreover, the disease control was significantly better in the sorafenib group than in the placebo group (43 vs. 32%, P=0.002). However, the adverse events were also more frequent in the sorafenib group (80 vs. 52%). These effects were mainly of grade 1 or 2 in severity and included diarrhea, weight loss, HFSR, anorexia and alopecia.

These results were affirmed by the results from the Asia-Pacific trial, which enrolled patients with similar eligibility criteria. The median OS was 6.5 months in the sorafenib group compared with 4.2 months in the placebo group, while the median time to progression was also significantly prolonged in the sorafenib vs. the placebo group (2.8 vs. 1.4 months; P=0.0005) (15). The side effect profile was also similar to the SHARP trial.

Although both trials reported an increased adverse event frequency in sorafenib-treated patients, the drug was well-tolerated and the side effects were manageable (15,16). The absolute risk of discontinuation or dose reductions was low and could be mitigated by more aggressive monitoring and management.

In order to predict the long-term prognosis after resection of tumors, a preclinical study was undertaken to investigate the effects of sorafenib on tumor growth, recurrence and metastasis after curative resection of HCC in mice (17). This study revealed that sorafenib inhibited the recurrence and metastasis of HCC after HCC resection, producing a maximum of 88% reduction in intrahepatic recurrent tumor volume and a 100% reduction in lung metastasis. It also showed a 10.7-fold reduction in tumor recurrence. A phase III study to evaluate the use of sorafenib to prevent recurrence and to improve survival after surgical resection or local ablation (STORM study) is currently underway.

Thyroid cancer. Three phase II studies have been conducted to determine the efficacy of sorafenib in advanced follicular thyroid cancer (18). These studies showed that sorafenib had significant activity with partial responses ranging from 15-25% and stabilization of the disease occurring in an additional 34-56% of the patients. The median PFS ranged from 13.5 to 19.6 months. Furthermore, the overall safety profile was acceptable and adverse events were consistent with other sorafenib trials (19). In light of these promising results, a phase III study evaluating the efficacy and safety of sorafenib in advanced/metastatic iodine refractory thyroid cancer was initiated (18). Additionally, some guidelines have begun to recommend sorafenib in patients with iodine-refractory progressive metastatic disease who are not willing or able to enter previous clinical trials.

However, in some other cancers like melanoma, sorafenib monotherapy still continues to elude clinical benefit. As mentioned before there is a strong preclinical and clinical evidence supporting the role of B-Raf in driving melanoma progression. In spite of this, sorafenib, being a B-Raf inhibitor, did not demonstrate significant activity in advanced melanoma patients (20,21). Subsequent preclinical studies also showed that sorafenib treatment just led to minor inhibition of B-Raf with many off-target effects (21). Therefore, sorafenib alone did not offer much benefit in melanoma treatment. Similar results were observed in many other types of cancers, of which some are summarized in Table II.
5. Sorafenib combination therapy

Sorafenib has various characteristics that suggest it would be a useful combination treatment option for advanced malignancies. The targeting of multiple Raf isoforms and various tyrosine kinase inhibitors may help overcome multidrug resistant genes (2). Also its ability to induce apoptosis in various tumors could complement the cytotoxic effects of standard chemotherapies. Evidence also suggests that inhibition of Raf-1 by sorafenib can resensitize tumor cells to radiation and chemotherapy (2). Moreover, the use of sorafenib in combination with other drugs means that the doses can be reduced and hence it might help alleviate the side effects of the drugs. Owing to these reasons and the limitations of monotherapy, its role in combination with other agents has been widely explored. A figure summarizing the mode of action of combination agents used with sorafenib is shown in Fig. 2.

Sorafenib and other targeted agents. A phase I dose-escalation trial of sorafenib and bevacizumab was performed at below-recommended single-agent doses involving 39 patients with various cancers (22). This combination showed promising clinical activity especially in ovarian cancer. However, the rapidity and frequency of dose reductions indicated an intolerable long-term dosage and the need for alternative dosing schedules. Recently another phase I study reported that intermittent sorafenib dosing with bevacizumab has clinical activity, fewer patients require a sorafenib dose reduction and fewer side effects are observed (23).

The combination of sorafenib with erlotinib was investigated in a phase I trial which reported that the combination was well-tolerated and showed promising activity (24). In a phase II trial for the combination, a higher PFS and OS was seen in the EGFR wild-type and the EGFR FISH-negative patients compared to erlotinib alone (25). However, additional
studies are needed to confirm the benefit of this combination. Recently, a preclinical study of the combination of sorafenib with erlotinib or cetuximab showed synergistic antitumor activity in both colorectal cancer and NSCLC (26).

A phase I study that investigated sorafenib plus IFN-α-2a in advanced RCC and melanoma showed preliminary antitumor activity and the doses were well-tolerated (27). Another study investigating sorafenib with IFN-α-2b in advanced RCC patients showed substantial activity, but the toxicity exceeded that of either drug alone (28). However, dose reductions and breaks between cycles allowed for long term therapy. In contrast, a more recent phase II study that investigated the combination of sorafenib and pegylated IFN-α-2b in metastatic melanoma patients showed modest clinical activity and some serious side effects including fatal bleeding complications (29). This may have been due to a different dosing schedule or the use of Peg-IFN-α-2b instead of conventional IFN-α. Additional studies are summarized in Table III.

Sorafenib and chemotherapy. Sorafenib in combination with doxorubicin was studied in a phase I dose escalating study in patients with advanced solid tumors, which showed that the increasing dose did not result in significant toxicity and also promising efficacy results were observed (30). Subsequently, a phase II double-blind study was conducted in patients with advanced HCC (31). The median time to progression, OS and PFS were greater with sorafenib plus doxorubicin compared to doxorubicin alone. The degree to which this improvement represents synergism remains to be defined.

An alternative combination with sorafenib, docetaxel and cisplatin was studied as a phase II study in gastric and gastro-esophageal junction adenocarcinoma (32). This study showed encouraging efficacy with a tolerable toxicity and hence further investigations are warranted.

A phase I study with sorafenib, carboplatin and paclitaxel (CP) on advanced NSCLC showed encouraging antitumor activity and manageable adverse effects (33,34). However, in a phase III randomized, double blind trial, no clinical benefit was observed from adding sorafenib to CP as first-line treatment for NSCLC. Likewise in another phase III trial, the addition of sorafenib to CP did not improve PFS or OS over placebo plus CP and hence cannot be recommended in the second-line setting for patients with advanced melanoma (35).

A phase II study with sorafenib, gemcitabine and capecitabine (GC) in advanced RCC has also shown encouraging results (36). The PFS and response rates were greater than those observed with sorafenib monotherapy or GC and also the adverse events were manageable. Additional studies are summarized in Table III.

Sorafenib and radiotherapy. The spectrum of kinase inhibition and the toxicity profile of sorafenib increases its potential to synergize with radiation through various mechanisms, such as proliferation inhibition, vascular normalization and interference with intracellular signaling pathways (37). Evidence has suggested that Raf-1 caused radiation resistance through an increased radiation-induced potentially lethal damage repair capacity in HCC cell lines (38). Thus targeting these molecules via sorafenib will re-sensitize these cells to radiation.

Plastaras et al demonstrated that sorafenib did not affect cell survival in vitro, but altered the radiation response in a schedule-dependent manner in vivo, with radiation treatment followed sequentially by sorafenib being associated with the greatest antitumor activity (39).

Similar results were observed in another preclinical study, which investigated the effect of sorafenib plus radiation on colorectal cancer cell lines (37). Sorafenib had little effect on radiation response in vitro but was highly effective in vivo, suggesting that inhibition of proliferation and interference with angiogenesis may be the basis for the interaction. However, there was an interesting observation in the investigation of the timing of sorafenib and radiation through the inhibition assay. A significant growth inhibition was observed when sorafenib was given 2 h after radiation in the HT29 cell line. This correlates with the results of Plastaras et al, although their conclusion was derived from in vivo studies (39). Following these promising results, studies are currently underway investigating the efficacy in other tumor types as well (37).

6. Conclusions

The enhanced understanding of the etiology of cancer has led to an era of molecular targeted therapies that aim to achieve tumor selectivity and limit drug-related toxicities. Sorafenib has emerged as a promising means of addressing these issues with its multiple mechanisms of action and favorable safety and efficacy profile. This resulted in its FDA approval for the treatment of advanced RCC and HCC. However, in many other cancers, it is still limited in activity due to reasons not clearly understood. Fortunately the utility of sorafenib in cancer therapy does not end with this, because its unique and multiple mechanisms of action on tumor and tumor microvasculature has proven valuable when combined with other anticancer therapies, such as other molecular targeted agents, chemotherapy and radiotherapy. A growing body of clinical research supports these combinations and expects that these novelties will soon make their way into cancer treatments. Therefore, sorafenib has not yet failed its original promise. Future issues include identifying optimal combinations, treatment schedules and dosage of sorafenib combinations for a variety of tumor types. In addition, the appropriate biomarkers for improved patient selection and response end-points need to be defined and validated in order to improve the benefits of sorafenib treatment.

References


